Generic selectors
Exact matches only
Search in title
Search in content
Filter by Categories
15th National Conference of the IAOMFP, Chennai, 2006
Abstract
Abstracts from current literature
Acne in India: Guidelines for management - IAA Consensus Document
Addendum
Announcement
Art & Psychiatry
Article
Articles
Association Activities
Association Notes
Award Article
Book Review
Brief Report
Case Analysis
Case Letter
Case Letters
Case Notes
Case Report
Case Reports
Clinical and Laboratory Investigations
Clinical Article
Clinical Studies
Clinical Study
Commentary
Conference Oration
Conference Summary
Continuing Medical Education
Correspondence
Corrigendum
Cosmetic Dermatology
Cosmetology
Current Best Evidence
Current View
Derma Quest
Dermato Surgery
Dermatopathology
Dermatosurgery Specials
Dispensing Pearl
Do you know?
Drug Dialogues
e-IJDVL
Editor Speaks
Editorial
Editorial Remarks
Editorial Report
Editorial Report - 2007
Editorial report for 2004-2005
Errata
Erratum
Focus
Fourth All India Conference Programme
From Our Book Shelf
From the Desk of Chief Editor
General
Get Set for Net
Get set for the net
Guest Article
Guest Editorial
History
How I Manage?
IADVL Announcement
IADVL Announcements
IJDVL Awards
IJDVL AWARDS 2015
IJDVL Awards 2018
IJDVL Awards 2019
IJDVL Awards 2020
IJDVL International Awards 2018
Images in Clinical Practice
In Memorium
Inaugural Address
Index
Knowledge From World Contemporaries
Leprosy Section
Letter in Response to Previous Publication
Letter to Editor
Letter to the Editor
Letter to the Editor - Case Letter
Letter to the Editor - Letter in Response to Published Article
LETTER TO THE EDITOR - LETTERS IN RESPONSE TO PUBLISHED ARTICLES
Letter to the Editor - Observation Letter
Letter to the Editor - Study Letter
Letter to the Editor - Therapy Letter
Letter to the Editor: Articles in Response to Previously Published Articles
Letters in Response to Previous Publication
Letters to the Editor
Letters to the Editor - Letter in Response to Previously Published Articles
Letters to the Editor: Case Letters
Letters to the Editor: Letters in Response to Previously Published Articles
Medicolegal Window
Messages
Miscellaneous Letter
Musings
Net Case
Net case report
Net Image
Net Letter
Net Quiz
Net Study
New Preparations
News
News & Views
Obituary
Observation Letter
Observation Letters
Oration
Original Article
ORIGINAL CONTRIBUTION
Original Contributions
Pattern of Skin Diseases
Pearls
Pediatric Dermatology
Pediatric Rounds
Perspective
Presedential Address
Presidential Address
Presidents Remarks
Quiz
Recommendations
Regret
Report
Report of chief editor
Report of Hon : Treasurer IADVL
Report of Hon. General Secretary IADVL
Research Methdology
Research Methodology
Resident page
Resident's Page
Resident’s Page
Residents' Corner
Residents' Corner
Residents' Page
Retraction
Review
Review Article
Review Articles
Revision Corner
Self Assessment Programme
SEMINAR
Seminar: Chronic Arsenicosis in India
Seminar: HIV Infection
Short Communication
Short Communications
Short Report
Special Article
Specialty Interface
Studies
Study Letter
Supplement-Photoprotection
Supplement-Psoriasis
Symposium - Contact Dermatitis
Symposium - Lasers
Symposium - Pediatric Dermatoses
Symposium - Psoriasis
Symposium - Vesicobullous Disorders
SYMPOSIUM - VITILIGO
Symposium Aesthetic Surgery
Symposium Dermatopathology
Symposium-Hair Disorders
Symposium-Nails Part I
Symposium-Nails-Part II
Systematic Reviews and Meta-analysis
Tables
Technology
Therapeutic Guidelines
Therapeutic Guidelines - IADVL
Therapeutics
Therapy
Therapy Letter
View Point
Viewpoint
What’s new in Dermatology
View/Download PDF

Translate this page into:

Letter to the Editor - Therapy Letter
2020:86:6;726-729
doi: 10.4103/ijdvl.IJDVL_814_19
PMID: 33063707

Primary cutaneous CD4+ small/medium pleomorphic T-cell lymphoproliferative disorder in a woman successfully treated with intralesional interleukin injection and occlusive corticosteroid

Yuyang Jiang, Donghua Liu, Alya Alnasri
 Department of Dermatology and Venereology, First Affiliated Hospital of Guangxi Medical University, Nanning, China

Correspondence Address:
Donghua Liu
Department of Dermatology and Venereology, First Affiliated Hospital of Guangxi Medical University, No. 6, Shuang Yong Road, Nanning
China
Published: 13-Oct-2020
How to cite this article:
Jiang Y, Liu D, Alnasri A. Primary cutaneous CD4+ small/medium pleomorphic T-cell lymphoproliferative disorder in a woman successfully treated with intralesional interleukin injection and occlusive corticosteroid. Indian J Dermatol Venereol Leprol 2020;86:726-729
Copyright: (C)2020 Indian Journal of Dermatology, Venereology, and Leprology

Sir,

Primary cutaneous CD4+ small/medium pleomorphic T-cell lymphoproliferative disorder can manifest as a single invasive plaque, nodule or tumour. The most common presentation is as a localized lesion and multiple lesions are rare. Currently, this disease is treated with local excision, radiation therapy, topical intralesional steroids, oral doxycycline or autologous stem cell transplant. Herein, we report a case of this disease which could be completely treated with intralesional interleukin injection and topical occlusive corticosteroid.

A 28-year-old woman presented with a painless nodule on her nose of one month duration. On clinical examination, there was a solitary, firm, hemispherical, dark-red erythematous nodule, with shiny surface and telangiectases, located on the right ala of the nose, of 1.8 × 1.5 cm size [Figure - 1]a.

On laboratory examination, the complete blood count was normal. Histopathological examination of the nodule showed a dense infiltration of small to medium pleomorphic mononuclear cells in the dermis [Figure - 2]d. The epidermis was spared, but there was infiltration into the pilosebaceous units and sweat gland [Figure - 2]a and [Figure - 2]b. Some of the neoplastic cells had irregular nuclear contours with hyper-chromatism. There was neither eosinophil nor plasma cell infiltration [Figure - 2]c. The immunohistochemical staining revealed that the neoplastic cells strongly expressed CD3, CD4 and PD-1 positive 'pseudo-rosettes”. [Figure - 3]a and [Figure - 3]d. The neoplastic cells were negative for CD10, Mum1, TIA-1 and Tdt. There were few reactive CD8+ T cells and CD20+ B cells [Figure - 3]b and [Figure - 3]c. Proliferative index (Ki67) was approximately 30%. EBV-encoded small RNA was negative. Thus a final diagnosis of primary cutaneous CD4+ small/medium pleomorphic T-cell lymphoproliferative disorder was made.

The patient received an intralesional injection of 5lakh IU of interleukin-2 as well as one daily occlusion with flumetasone ointment for 3 weeks. The nodule disappeared completely [Figure - 1]b with no recurrence in even after 11 months of treatment.

Primary cutaneous CD4+ small/medium pleomorphic T-cell lymphoproliferative disorder, defined by a predominance of small- to medium-sized CD4+ pleomorphic T-cells,[1] often occurs as a single invasive plaque, nodule or tumour, without the typical macule and plaque stage of mycosis fungoides. In the 2018 WHO-EORTC classification update for primary cutaneous lymphomas, the term primary cutaneous CD4 positive small/medium T-cell lymphoma was modified to lymphoproliferative disorder.[1] The low clinical risk, localized disease and similarity to clonal drug reactions suggested that this entity should no longer be classified as an overt cutaneous lymphoma. It is characterized by a relatively indolent clinical behavior and an uncertain malignant potential. The frequency of the disease is 9% and the five-year disease-specific survival is 99%.[1] The disease is known to have a good prognosis and in order to avoid metastasis, positive treatment is still recommended. Therefore, the diagnosis requires a careful morphologic and immunophenotypic analysis, as well as molecular genetic studies.[2]

The differential diagnosis of the disease includes cutaneous lymphoid hyperplasia, mycosis fungoides, primary cutaneous follicle center lymphoma and primary cutaneous marginal zone lymphoma. The most significant difference between cutaneous lymphoid hyperplasia and this disease are the lymphocytic atypia and the loss of the pan T-cell markers. In the past, the disease was often misdiagnosed as mycosis fungoides, which classically progresses through patch, plaque and tumor stages, besides PD-1 is rarely expressed. The histopathological examination of primary cutaneous follicle center lymphoma reveals the proliferation of bcl 6+, bcl 2- follicle center cells. Another disease named primary cutaneous marginal zone lymphoma show clonal immunoglobulin rearrangements and negative CD4. Similarity in the clinical manifestation makes the diagnosis difficult, but histopathology, immunohistochemistry and molecular genetics can discriminate among those diseases. A literature review showed that the disease has no sex predominance and the prognosis was not age-related.[2] The lesion has certain common characteristics such as single lesion, small size (<3 cm), no ulceration and a low proliferative index. After topical therapy, a few cases have recurred in situ, while some recurred elsewhere and a few did not relapse. None of them had received chemotherapy.[3]

The optimal treatment for this disease is not yet defined. The treatment includes surgical resection, systemic chemotherapy, radiotherapy or immunotherapy, as well as topical corticosteroids. Of note, in a previous case report, it was mentioned that the nodule can even spontaneously regress after biopsy.[4]

According to literature, intralesional interleukin injection has been proved to have a therapeutic effect on lymphomas.[5] Considering the anti-tumor and immune enhancement effects of interleukin, we used intralesional interleukin injection in the treatment of this lymphoproliferative disorder.

In this study, the positive prognostic factors include the singularity of the lesion, small size (<3 cm) and the absence of ulceration. In conclusion, we have presented a a rare case, successfully treated by using a combination treatment of intralesional interleukin injection and occlusive corticosteroid ointment.

Acknowledgement

We would like to express my great appreciation to Prof. Yongyao Gu (Pathology Department, First Affiliated Hospital of Guangxi Medical University).

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent forms. In the form, the patient has given her consent for her images and other clinical information to be reported in the journal. The patient understand that name and initials will not be published and due efforts will be made to conceal identity, but anonymity cannot be guaranteed.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

References
1.
Willemze R, Cerroni L, Kempf W, Berti E, Facchetti F, Swerdlow SH, et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood 2019;133:1703-14.
[Google Scholar]
2.
Jain G, Aiyer HM. Primary cutaneous CD4 positive small/medium T cell lymphoma. Indian J Dermatol Venereol Leprol 2018;84:186-8.
[Google Scholar]
3.
Maurelli M, Colato C, Gisondi P, Girolomoni G. Primary cutaneous CD4+ small/medium pleomorphic T-cell lymphoproliferative disorder: A case series. J Cutan Med Surg 2017;21:502-6.
[Google Scholar]
4.
González Fernández D, Valdés Pineda F, Gómez Díez S, Vivanco Allende B. Primary cutaneous CD4+small/medium-Sized T-cell lymphoma with spontaneous regression after biopsy. Actas Dermosifiliogr 2015;106:767-8.
[Google Scholar]
5.
Querfeld C, Rosen ST, Guitart J, Rademaker A, Foss F, Gupta R, et al. Phase II trial of subcutaneous injections of human recombinant interleukin-2 for the treatment of mycosis fungoides and Sézary syndrome. J Am Acad Dermatol 2007;56:580-3.
[Google Scholar]

Fulltext Views
648

PDF downloads
137
Show Sections